Featured Articles

  1. U.S. Tariffs And Their Tenuous Impact On Clinical Trials 6/10/2025

    RSM US LLP Life Sciences Senior Analyst Amanda Laskey discusses Trump administration tariffs and how they're expected to impact the pharma world, specifically clinical research.

  2. Bracing For The Impact Of The Federal Workforce Reduction 6/9/2025

    The federal workforce reductions pose significant challenges for the life sciences industry, particularly for R&D, supply chain oversight, and industry workforce development.

  3. Life Sciences Business Strategies For Trump 2.0 Policy Changes 6/6/2025

    Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

  4. Winning Management Strategies For Early And Late-Stage Drug Development 6/4/2025

    Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early and late-stage drug development, explains Halloran's Carolina Ahrendt.

  5. Companies To Watch: Vivani Medical 5/30/2025

    Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.

  6. Milestone Payments: Potential Trouble In The Last Mile? 5/23/2025

    Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially when milestone payments are involved, explain experts ta Venable LLP.

  7. Implications Of California's AB 824 Patent Settlement Regulation 5/21/2025

    California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB 824 presumes, for example, that "reverse payment" agreements are illegal.

  8. Reactive To Proactive: A Major Shift In The Fight Against Alzheimer's 5/19/2025

    Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and new drug development, writes Mike Banville, CEO and President at ALZpath.

  9. Innovative Strategies In Early Commercialization: A Leader's Perspective 5/16/2025

    For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a perfect plan, writes Melinta Therapeutics CEO John Harlow.

  10. Promoting A Newly Approved Indication Against Established Competitors 5/14/2025

    In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.